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Abstract
Background: IL12B encodes the p40 subunit of IL-12, which is also part of IL-23. Recent genome-wide association studies
identified IL12B and IL23R as susceptibility genes for inflammatory bowel disease (IBD). However, the phenotypic effects and
potential gene-gene interactions of IL12B variants are largely unknown.
Methodology/Principal Findings: We analyzed IL12B gene variants regarding association with Crohn’s disease (CD) and
ulcerative colitis (UC). Genomic DNA from 2196 individuals including 913 CD patients, 318 UC patients and 965 healthy,
unrelated controls was analyzed for four SNPs in the IL12B gene region (rs3212227, rs17860508, rs10045431, rs6887695). Our
analysis revealed an association of the IL12B SNP rs6887695 with susceptibility to IBD (p=0.035; OR 1.15 [95% CI 1.01–1.31]
including a trend for rs6887695 for association with CD (OR 1.41; [0.99–1.31], p=0.066) and UC (OR 1.18 [0.97–1.43],
p=0.092). CD patients, who were homozygous C/C carriers of this SNP, had significantly more often non-stricturing, non-
penetrating disease than carriers of the G allele (p=6.8610
25; OR=2.84, 95% CI 1.66–4.84), while C/C homozygous UC
patients had less often extensive colitis than G allele carriers (p=0.029; OR=0.36, 95% CI 0.14–0.92). In silico analysis
predicted stronger binding of the minor C allele of rs6887695 to the transcription factor RORa which is involved in Th17
differentiation. Differences regarding the binding to the major and minor allele sequence of rs6887695 were also predicted
for the transcription factors HSF1, HSF2, MZF1 and Oct-1. Epistasis analysis revealed weak epistasis of the IL12B SNP
rs6887695 with several SNPs (rs11889341, rs7574865, rs7568275, rs8179673, rs10181656, rs7582694) in the STAT4 gene
which encodes the major IL-12 downstream transcription factor STAT4 (p,0.05) but there was no epistasis between IL23R
and IL12B variants.
Conclusions/Significance: The IL12B SNP rs6887695 modulates the susceptibility and the phenotype of IBD, although the
effect on IBD susceptibilty is less pronounced than that of IL23R gene variants.
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Introduction
The identification of the IL-23/Th17 pathway as a key
regulator of intestinal immune homeostasis and proinflammatory
responses in defense to microbial infection has elucidated new
potential therapeutic targets in inflammatory bowel diseases (IBD)
[1,2,3,4]. Genome-wide association studies (GWAS) and large
cohort studies demonstrated that IL23R [3,5,6,7] and additional
genes involved in Th17 differentiation (e.g., IL12B, JAK2, TYK2,
STAT3, CCR6, IL2/IL21 and TNFSF15) are associated with the
susceptibility to Crohn’s disease (CD) and partly also to ulcerative
colitis (UC) [5,8,9,10,11]. Moreover, a pathway analysis using data
from the Wellcome Trust Case Control Consortium (WTCCC)
uncovered significant associations of CD and IL-12/IL-23
pathway components, harbouring 20 genes such as IL12B, JAK2,
STAT3 and CCR6 [12]. Functionally, the proinflammatory
cytokines IL-12 and IL-23 play critical and unique roles in
bridging the innate and adaptive immune systems in IBD [4,13]
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30and are produced primarily by activated dendritic cells (DCs) and
macrophages in response to microbial stimulation. IL-12 promotes
the differentiation of naive CD4+ T cells into mature interferon-c
(IFN-c)-producing Th1 effector cells and is a potent stimulus of
natural killer and CD8+ T cells [14,15]. In contrast, IL-23, a
heterodimeric cytokine composed of a p19 subunit and a p40
subunit of which the latter is shared with IL-12, is required for the
generation of memory T cells and drives differentiation of Th17
cells [16,17]. Th17 cytokines such as IL-17A, IL-17F, IL-21, IL-
22, IL-26 and the Th17 chemokine CCL20 have been particularly
implicated as key cytokines involved in the intestinal inflammation
of CD [1,18,19,20,21,22,23].
On the genetic level, IL12B encodes the IL-12 p40 subunit
shared by IL-12 and IL-23 cytokines while IL23R encodes one of
the two subunits of the IL-23 receptor [24]. Antibody therapy
directed against the IL-12/IL-23 p40 subunit demonstrated some
clinical efficacy in CD patients [25]. Since the first identification of
IL23R as susceptibility gene in IBD by Duerr et al. [3], various
GWAS and cohort studies have confirmed IL23R not only as a
major susceptibility gene in IBD but also in the pathogenesis of
other autoimmune diseases such as psoriasis [26,27] and
ankylosing spondylitis [28], implicating common proinflammatory
pathways. Genetic variants in the IL12B region have also been
associated with the susceptibility to psoriasis, ankylosing spondy-
litis, and infectious diseases such as leprosy and tuberculosis
[29,30,31,32,33]. In contrast, data on IL12B variants and their
role in asthma [34,35], rheumatoid arthritis [36] or multiple
sclerosis [37] remain controversial. While recent GWAS meta-
analyses by Barrett et al. [5], Franke et al. [9], and Anderson et al.
[10] established IL12B as IBD susceptibility gene, smaller studies
showed inconsistent results [38,39]. Cohort studies in the Spanish
[38] and Japanese [39] population demonstrated an association of
IL12B SNPs with the susceptibility to IBD; however with different
results, reporting associations with CD susceptibility in the
Japanese cohort (rs6887695) [39] and to UC (rs6887695) but not
to CD susceptibility in the Spanish cohort [38]. Moreover, the
phenotypic effects of IL12B and potential gene-gene interactions
contributing to IBD susceptibility are largely unknown.
Since the exact role of IL12B for IBD susceptibility in the
German population and IBD phenotype behaviour remains
unclear, we aimed to perform a detailed genotype-phenotype
analysis in a large IBD cohort and an analysis for potential
epistatic interactions with other gene variants involved in IL-12
and IL-23 signaling and implicated in IBD susceptibility such as
IL23R and STAT4 [3,40] which encodes the major IL-12-induced
downstream transcription factor STAT4.
Methods
Ethics statement
The study was approved by the Ethics committee of the Medical
Faculty of Ludwig-Maximilians-University Munich and written,
informed consent was obtained from all patients prior to the study.
Study protocols adhered to the ethical principles for medical
research involving human subjects of the Helsinki Declaration (as
detailed under: http://www.wma.net/en/30publications/10policies/
b3/index.html).
Study population and IBD phenotype assessment
Overall, the study population (n=2196) consisted of 1231 IBD
patients including 913 patients with CD, 318 patients with UC,
and 965 healthy, unrelated controls, all of Caucasian origin. The
demographic and clinical data (behaviour and location of IBD,
disease-related complications, immunosuppressive therapy and
history of previous surgeries) of the patients were recorded by
analysis of patient charts and a detailed questionnaire including an
interview at time of enrolment. The diagnosis of CD or UC was
determined according to established guidelines based on endo-
scopic, radiological, and histopathological criteria. Patients with
CD were assessed following the Montreal classification based on
the age at diagnosis (A), location (L), and behaviour (B) of the
disease [41]. In patients with UC, anatomic location was also
based on the Montreal classification using the criteria ulcerative
proctitis (E1), left-sided UC (distal UC; E2), and extensive UC
(pancolitis; E3). Patients with indeterminate colitis were excluded
from the study. The demographic characteristics of the IBD study
population were collected blind to the results of the genotype
analyses and are summarized in Table 1.
DNA extraction and genotyping of the IL12B variants
From all study participants, blood samples were taken and
genomic DNA was isolated from peripheral blood leukocytes using
the DNA blood mini kit from Qiagen (Hilden, Germany)
according to the manufacturer’s guidelines. Four IL12B SNPs
(rs3212227, rs17860508, rs10045431 and rs6887695) were
genotyped by PCR and melting curve analysis using a pair of
fluorescence resonance energy transfer (FRET) probes in a
LightCyclerH 480 Instrument (Roche Diagnostics, Mannheim,
Germany) as described in previous studies [6,40,42,43]. These
IL12B SNPs were selected based on previous studies showing
associations with CD or other autoimmune diseases such as
psoriasis. Specifically, the SNPs rs3212227 and rs6887695 were
selected from the study of Cargill and co-workers [29], while
rs6887695 was also investigated in the study of Parkes et al. [8].
The SNP rs10045431 was selected from the study of Barrett and
co-workers [5]. Additionally, the SNP rs17860508 located within
the promoter of IL12B was included because of its potential
functional relevance regarding gene expression [44]. The total
Table 1. Demographic characteristics of the IBD study
population.
Crohn’s
disease
n=913
Ulcerative
colitis
n=318
Controls
n=965
Gender
Male (%) 48.9 52.2 63.5
Female (%) 51.1 47.8 36.5
Age (yrs)
Mean 6 SD 40.9613.2 44.2614.8 46.0610.3
Range 15–83 17–88 19–68
Body mass index
Mean 6 SD 23.064.2 23.964.5
Range 13–41 15–54
Age at diagnosis (yrs)
Mean 6 SD 26.1612.3 28.9614.5
Range 1–78 2–81
Disease duration (yrs)
Mean 6 SD 13.468.9 12.268.3
Range 0–47 1–50
Positive family history
of IBD (%)
16.8 17.4
doi:10.1371/journal.pone.0034349.t001
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1| Light Cycler 480 Genotyping Master Mix (Roche Diagnos-
tics), 2.5 pmol of each primer and 0.75 pmol of each FRET probe
(TIB MOLBIOL, Berlin, Germany). In the case of rs3212227 and
rs10045431, the concentrations of the forward primers and in the
case of rs17860508 the concentration of the reverse primer was
reduced to 0.5 pmol. In the case of rs6887695 the concentration of
the reverse primer was reduced to 1.25 pmol and in the case of
rs744166 the concentration of the forward primer was reduced to
0.75 pmol, respectively. Two SNPs were analyzed in a multiplex
reaction, the combinations were rs3212227+rs17860508 and
rs10045431+rs6887695. The PCR comprised an initial denatur-
ation step (95uC for 10 min) and 45 cycles (95uC for 10uC sec, 60
for 10 sec, 72uC for 15 sec). The melting curve analysis comprised
an initial denaturation step (95uC for 1 min), a step rapidly
lowering the temperature to 40uC and holding for 2 min, and a
heating step slowly (1 acquisition/uC) increasing the temperature
up to 95uC and continuously measuring the fluorescence intensity.
The results of the melting curve analysis were confirmed by
analyzing two patient samples for each possible genotype using
sequence analysis. For sequencing, the total volume of the PCR was
100 ml containing 250 ng of genomic DNA, 1| PCR-buffer
(Qiagen, Hilden, Germany), a final MgCl2 concentration of 2 mM,
0.5 mM of a dNTP mix (Sigma, Steinheim, Germany), 2.5 units of
HotStar Plus Taq
TM DNA polymerase (Qiagen) and 10 pmol of
each primer (TIB MOLBIOL). The PCR comprised an initial
denaturation step (95uC for 5 min), 35 cycles (denaturation at 94uC
for 30 sec, primer annealing at 65uC for 30 sec, extension at 72uC
for 30 sec) and a final extension step (72uC for 10 min). The PCR
products were purified using the QIAquick PCR Purification Kit
(Qiagen) and sequenced by a commercial sequencing company
(Sequiserve, Vaterstetten, Germany). All sequences of primers and
FRET probes and primer annealing temperatures used for
genotyping and for sequence analysis, respectively, are given in
Supplementary Tables S1 and S2.
STAT4 and IL23R genotyping
For analysis of epistatic interactions, seven STAT4 SNPs
(rs11889341, rs7574865, rs7568275, rs8179673, rs10181656,
rs7582694, rs10174238) and 10 IL23R SNPs (rs1004819,
rs7517847, rs10489629, rs2201841, rs11465804, rs11209026=
p.Arg381Gln, rs1343151, rs10889677, rs11209032, rs1495965)
were genotyped by PCR and melting curve analysis using a pair of
fluorescence resonance energy transfer (FRET) probes in a
LightCyclerH 480 Instrument (Roche Diagnostics, Mannheim,
Germany) as described previously [6,40]. The majority of IL23R
and STAT4 genotype data were available from previous studies
[6,40].
In silico analysis of transcription factor binding sites
SNPs rs3212227, rs17860508, rs10045431 and rs6887695 were
analyzed for potential transcription factor binding sites applying
the online tool TFSEARCH (http://www.cbrc.jp/research/db/
TFSEARCH.html). It is based on the TRANSFAC database
developed at GBF Braunschweig, Germany [45]. The threshold
score for binding sites was set to 75.0 (score=100.0 * (‘weighted
sum’2min)/(max2min); max. score=100). For each SNP, major
and minor alleles including the flanking sequences 15 bp upstream
and downstream were analyzed. Only human transcription factors
were included in the analysis.
Statistical analyses
Power calculation was performed using the Genetic Power
Calculator (http://pngu.mgh.harvard.edu/,purcell/gpc/). Each
genetic marker was tested for Hardy-Weinberg equilibrium in the
control population. For data evaluation, we used PLINK (http://
pngu.mgh.harvard.edu/,purcell/plink/) and R-2.13.1. (http://
cran.r-project.org). Haplotypes tests were performed in a sliding-
window approach including up to 4 markers. Epistasis between
different SNPs was tested using the –epistasis option on PLINK.
Genotype-phenotype associations were assessed using logistic
regression.
Results
The IL12B polymorphisms rs6887695 is associated with
increased IBD susceptibility
In all three subgroups (CD, UC, and controls), the allele
frequencies of the IL12B SNPs (rs3212227, rs17860508,
rs10045431, rs6887695) were in accordance with the predicted
Hardy-Weinberg equilibrium (Table 2). The IL12B SNP
rs6887695 showed an association with increased IBD susceptibility
(p=0.035; OR 1.15 [95% CI 1.01–1.31]). In addition, there was a
trend for rs6887695 for association with CD (OR 1.41 [95% CI
0.99–1.31], p=0.066) and UC (OR 1.18 [95% CI 0.97–1.43],
p=0.092) and a trend for association of rs10045431 with UC (OR
0.83 [95% 0.68–1.02], p=0.083; Table 2).
IL12B haplotype analysis
We next performed a detailed haplotype analysis in our IBD
cohort. As shown in Tables 3 and 4, we could not demonstrate
significant associations of IL12B haplotypes with CD and UC
susceptibility. A haplotype of all four investigated SNPs
(rs3212227-rs17860508-rs10045431-rs6887695) showed a trend
for association with CD (p=0.053); however, this potential
association signal did not reach statistical significance and was
uncorrected for multiple testing.
Genotype-phenotype analysis: C/C homozygosity for the
SNP rs6887695 is associated with non-stricturing,
non-penetrating Crohn’s disease
The majority of previous GWAS meta-analyses showing an
association with IL12B were performed in CD patients with
predominant ileal involvement [5,9]. To exclude that only a
certain IBD subphenotype such as ileal CD is associated with
IL12B, we further investigated potential associations of IL12B
SNPs with the anatomic location in IBD patients Genotype-
phenotype analysis showed a weak association of rs3212227 with
colonic CD (p=0.04) but not with ileal involvement. In addition,
we analyzed the IL12B SNP rs6887695, for which we found a
trend for association with CD and UC, regarding potential
phenotypic consequences in CD and UC. CD patients, who were
homozygous C/C carriers of this SNP, had significantly more
often a non-stricturing, non-penetrating disease phenotype than
carriers of the G allele (=combined group of heterozygous C/G
and wildtype G/G carriers; p=6.8610
25 (Table 5). This strong
association remained significant following Bonferroni correction
for multiple testing. C/C homozygous carriers of the IL12B SNP
rs6887695 had also less stenoses than G carriers (p=0.038) and
there was a trend towards less penetrating disease (p=0.062), less
fistulas (p=0.085), and less surgery (p=0.063; Table 5). In UC,
homozygous C/C carriers of the IL12B SNP rs6887695 had
significantly more often left-sided UC (p=0.006) but less often
extensive UC (p=0.029) than the combined group of heterozy-
gous C/G and wildtype G/G carriers (Table 6).
IL12B in Inflammatory Bowel Disease
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variants regarding susceptibility to Crohn’s disease
Next, we analyzed potential evidence for epistasis of IL12B
variants with other CD susceptibility genes involved in IL-12 and
Th17 signaling, including CD-associated variants in the IL23R
and STAT4 gene [3,6,40]. Analysis for gene-gene interaction
revealed weak epistasis of IL12B SNP rs6887695 with 7 out of the
8 analyzed STAT4 gene variants (p,0.05) regarding CD
susceptibility (Table 7). However, following Bonferroni correction,
none of these associations remained significant. In addition, there
was no evidence for epistasis between IL23R and IL12B variants
(Table 7).
In silico analysis of IL12B SNPs identifies potential
differences in transcription factor binding to major and
minor alleles
To analyze if SNPs in the IL12B region modify the binding of
transcription factors to DNA and thereby modulating gene
expression, we analyzed SNPs rs3212227, rs17860508, rs10045431
and rs6887695 including the surrounding sequences for potential
binding sites as described in the methods section. The results are
shown in table 8. Interestingly, the highest differences in binding
scores for the major and the minor alleles was found for rs6887695,
the only SNP that was associated with overall IBD susceptibility in
our study cohort. Moreover, in homozygous carriers of the minor
allele of rs6887695, there were significant associations with specific
CD and UC phenotypes. While the transcription factors HSF1,
HSF2, MZF1 and Oct-1 were predicted to bind with very high
probability to the sequence comprising the major G allele, predicted
Table 3. Haplotypes of IL12B SNPs in the CD case-control
sample and omnibus p-values for association with CD
susceptibility.
Haplotype combination Omnibus p-value
rs3212227-rs17860508 0.957
rs17860508-rs10045431 0.333
rs10045431-rs6887695 0.168
rs3212227-rs17860508-rs10045431 0.219
rs17860508-rs10045431-rs6887695 0.202
rs3212227-rs17860508-rs10045431-rs6887695 0.053
P-values showing a trend towards significance are depicted in Italic fonts.
doi:10.1371/journal.pone.0034349.t003
Table 4. Haplotypes of IL12B SNPs in the UC case-control
sample and omnibus p-values for association with UC
susceptibility.
Haplotype combination Omnibus p-value
rs3212227-rs17860508 0.614
rs17860508-rs10045431 0.319
rs10045431-rs6887695 0.126
rs3212227-rs17860508-rs10045431 0.288
rs17860508-rs10045431-rs6887695 0.206
rs3212227-rs17860508-rs10045431-rs6887695 0.300
doi:10.1371/journal.pone.0034349.t004
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the other hand, the binding score for the transcription factor RORa
was higher for the minor C allele (Table 8). Therefore, differential
DNA binding of transcription factorsinthisgenomicregion followed
bydifferentialgenetranscriptionmightbeonereasonforthe disease-
modifying abilities of this SNP that we observed in our genotype-
phenotype analysis.
Discussion
This study presents a detailed genotype-phenotype analysis
investigating IL12B SNPs as potential susceptibility gene variants
in a large Caucasian IBD cohort. A major focus of this study was
the analysis of potential epistatic interactions with key gene
variants of the IL-12 and IL-23/Th17 pathway such as IL23R and
STAT4. We demonstrated that the IL12B variant rs6887695 is
weakly associated with overall IBD susceptibility (p=0.035), with
trends for association with both CD and UC susceptibility.
Moreover, a haplotype block formed by the four investigated
IL12B SNPs showed a trend for association with CD (p=0.05).
Considering our findings and the strong association signal for this
gene in the recent GWAS [9,10], IL12B can be regarded as
established IBD susceptibility gene. In contrast to the very large
IBD GWAS, our sample size (n=2196) was smaller, resulting in
limited power, particularly for the UC cohort. For example, a
power calculation, which assumed an OR of 1.2 and an allele
frequency of 0.20 for the rarest IL12B variant rs3212227,
demonstrated that our study had 63.1% power to detect a
nominal significant finding (alpha=0.05) in the CD cohort but
had only a power of 38.2% in the UC cohort. However, based on
the results of this study, the strength of a potential association of
IL12B with IBD is several log-fold weaker than that shown for
Table 5. Genotype-phenotype-analysis of SNP rs6887695 in patients with Crohn’s disease (CD).
IL12B (1) CC (2) CG (3) GG PCC ORCC
rs6887695 n=100 n=394 n=409 [95% CI]
Location
(n=768) n=80 n=331 n=357
Terminal ileum 11 55 46 1.000 0.92
(L1) (13.8%) (16.6%) (12.9%) [0.45–1.88]
Colon 6 43 49 0.158 0.53
(L2) (7.5%) (13.0%) (13.7%) [0.20–1.30]
Ileocolon 60 230 258 0.514 1.23
(L3) (75.0%) (69.5%) (72.3%) [0.70–2.17]
Upper GI 3 3 4 0.076 3.79
(L4) (3.8%) (0.9%) (1.1%) [0.76–16.69]
Behaviour
1
(n=690) n=72 n=293 n=325
Non-stricturing & Non-penetrating 31 65 75 6.8610
25* 2.84
(B1) (43.1%) (22.2%) (23.1%) [1.66–4.84]
Stricturing
(B2)
14
(19.4%)
87
(29.7%)
85
(26.2%)
0.160 0.63
[0.32–1.19]
Penetrating 27 141 165 0.062 0.61
(B3) (37.5%) (48.1%) (50.8%) [0.36–1.04]
0.36
9.5610
25* [0.21–0.62]
(B2+B3) (B2+B3)
Use of immuno-suppressive agents
2 50 202 225 0.604 0.84
(n=477/583) (79.7%) (82.1%) (82.1%) [0.42–1.69]
Surgery because of CD
3 35 188 200 0.063 0.63
(n=423/808) (42.2%) (52.9%) (54.2%) [0.39–1.027]
Fistulas 33 172 193 0.085 0.67
(n=398/825) (39.3%) (47.8%) (50.7%) [0.41–1.08]
Stenosis 42 221 225 0.038 0.62
(n=488/827) (48.3%) (61.1%) (59.5%) [0.39–0.98]
PCC: P-value for testing for differences between homozygous carriers of the C allele (C/C) and heterozygous and non-carriers of the C allele. ORCC: corresponding odds
ratios and 95% confidence intervals (95% CI). Significant P-values (,0.05) are depicted in bold, P-values showing a trend towards significance are depicted in Italic fonts.
P-values marked with an asterisk * remained significant after Bonferroni correction.
1Disease behaviour was defined according to the Montreal classification. A stricturing disease phenotype was defined as presence of stenosis without penetrating
disease. The diagnosis of stenosis was made surgically, endoscopically, or radiologically (using MRI enteroclysis).
2Immunosuppressive agents included azathioprine, 6-mercaptopurine, 6-thioguanin, methotrexate, infliximab and/or adalimumab.
3Only surgery related to CD-specific problems (e.g. fistulectomy, colectomy, ileostomy) was included.
doi:10.1371/journal.pone.0034349.t005
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such as NOD2 and ATG16L1 (Supplemental Table S3), suggesting
a more important role for IL-23R than IL-12/23 p40 in the
genetic susceptibility to IBD. This is in agreement with the recent
IBD meta-analyses [9,10], which showed much stronger IBD
association signals for IL23R than for IL12B. Similarly, smaller
studies failed to show an association of IL12B SNPs with IBD or
showed only weak associations with CD or UC [46,47,48] (see
Supplemental Table S4 for an overview on published studies on
IL12B in IBD). Even large studies such as the study by Festen
et al., which included 1,455 UC patients and 1,902 controls, was
unable to show an association of IL12B with UC [49], further
demonstrating that very large patient cohorts are necessary to
show convincing associations with this gene locus. Therefore,
IL23R is a more important genetic modifier of IBD susceptibility
than IL12B, suggesting a more important pathogenic role of Th17
cells, which express IL-23R, than Th1 cells, which develop under
the control of IL-12.
Currently, there are limited data on how IL12B may
functionally influence IBD susceptibility in humans. A very recent
study in mice demonstrated that a polymorphism in the coding
region of murine Il12b promotes IL-12p70 and IL-23 heterodimer
formation [50]. The authors hypothesized that the high synthesis
rate of IL-12/23 cytokines resulting from efficient binding may
lead to rapid proinflammatory skewing of immune responses and
disturbance of the homeostatic balance resulting in higher
susceptibility for IBD [50]. Other gene variants may also modulate
IL-12 expression as recently demonstrated by our group showing
increased basal levels of IL-12p40 in CD patients with two
mutated NOD2 alleles [51]. Currently, it is unclear which IL12B
SNP is the ‘‘true’’ disease-causing variant. We therefore performed
a detailed in silico analysis of IL12B regarding potential
transcription factor binding sites and demonstrated for
Table 6. Genotype-phenotype-analysis of SNP rs6887695 in patients with ulcerative colitis (UC) for which detailed phenotypic data
based on the Montreal classification was available.
IL12B (1) CC (2) CG (3) GG PCC ORCC
rs6887695 n=34 n=145 n=138 [95% CI]
Location
(n=193) n=25 n=94 n=74
Proctitis (E1) 3 10 11 1.000 0.96
(12.0%) (10.6%) (14.9%) [0.21–3.78]
0.030 [1.07–7.03]
(E1+E2) (E1+E2)
Left-sided UC (E2) 91 0 1 1 0.006* 3.94
(36.0%) (10.6%) (14.9%) [1.40–11.02]
Extensive UC (E3) 13 74 52 0.029 0.36
(52.0%) (78.7%) (70.3%) [0.14–0.92]
Extra-intestinal manifestations 3 26 24 0.747 0.66
(n=53/149) (27.3%) (35.1%) (37.5%) [0.13–2.91]
Use of immunosuppressive agents 22 97 82 0.818 1.23
(n=201/267) (78.6%) (77.6%) (71.9%) [0.45–3.57]
Abscesses 2 6 4 0.365 1.77
(n=12/240) (7.7%) (5.4%) (3.9%) [0.25–9.41]
For each variable, the number of patients included is given. PCC P-value for testing for differences between homozygous carriers of the C allele and heterozygous/non-
carriers of the C allele. ORCC: corresponding odds ratios and 95% confidence intervals (95% CI). Significant P-values (,0.05) are depicted in bold fonts. P-values marked
with an asterisk remained significant following Bonferroni correction.
doi:10.1371/journal.pone.0034349.t006
Table 7. Analysis for gene-gene interaction of IL12B with
IL23R and STAT4 variants, respectively, regarding susceptibility
to Crohn’s disease (CD).
IL12B SNPs rs3212227 rs17860508 rs10045431 rs6887695
IL23R SNPs
rs1004819 0.408 0.731 0.474 0.450
rs7517847 0.902 0.895 0.743 0.956
rs10489629 0.577 0.284 0.757 0.561
rs2201841 0.497 0.428 0.080 0.189
rs11465804 0.793 0.852 0.819 0.110
rs11209026=
p.Arg381Gln
0.280 0.752 0.929 0.181
rs1343151 0.970 0.745 0.874 0.971
rs10889677 0.485 0.688 0.108 0.120
rs11209032 0.311 0.473 0.890 0.427
rs1495965 0.641 0.640 0.518 0.624
STAT4 SNPs
rs11889341 0.732 0.092 0.160 0.025
rs7574865 0.845 0.069 0.223 0.031
rs7568275 0.725 0.115 0.229 0.045
rs8179673 0.659 0.120 0.160 0.035
rs10181656 0.618 0.115 0.230 0.040
rs7582694 0.818 0.085 0.162 0.021
rs10174238 0.354 0.200 0.625 0.247
Significant associations are highlighted in bold fonts. None of the associations
remained significant following Bonferroni correction.
doi:10.1371/journal.pone.0034349.t007
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PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e34349Table 8. Overview of potential transcription factor binding sites in the genomic regions harboring the analyzed IL12B SNPs
rs6887695, rs10045431, rs17860508, and rs3212227.
IL12B SNP Factor Consensus sequence
{
position relative
to SNP (59 to 39)
Binding score
major allele
Binding score
minor allele
rs6887695 (approx. 65 kb upstream of IL12B):
GTGTAGTGTAGTGGT[C/G]AATAGTCTGGATTTA
HSF2 NGAANNWTCK 21t o+8 85.9 68.6
AML-1a TGCGGT 26t o21 85.4 85.4
MZF1 NGNGGGGA 26t o+1 84.3 67.0
Oct-1 NNGAATATKCANNNN 25t o+9 82.5 70.6
AML-1a TGCGGT 214 to 29 81.4 81.4
AML-1a TGCGGT 29t o24 81.4 81.4
Th1/E4 NNNNGNRTCTGGMWTT 21t o+14 80.4 80.8
HSF1 RGAANRTTCN 21t o+8 79.0 62.7
RORa NWAWNNAGGTCAN 210 to +2 64.4 75.9
rs10045431 (approx. 57 kb upstream of IL12B):
GCAGGCACAGCCCAG[A/C]ATTAAACTCTCAAAT
Oct-1 CWNAWTKWSATRYN 22t o+11 79.6 75.5
SRY AAACWAM +4t o+10 77.3 77.3
Pbx-1 ANCAATCAW 22t o+6 75.5 69.6
Sp1 GRGGCRGGGW 211 to 22 75.3 75.3
Tst-1/Oct-6 NNKGAWTWANANTKN 24t o+10 70.8 81.2
rs17860508* (approx. 2.7 kb upstream of IL12B):
AATGTGGGGGCCACA[-/G/GC/TTAGA/TTAGAG]CCTCTCTCGGAGACA
GATA-3
& NNGATARGN 0 to +9 82.5 74.1
AML-1a TGCGGT 26t o21 83.7 83.7
AML-1a TGCGGT 213 to 28 82.7 82.7
MZF1 NGNGGGGA 213 to 26 80.9 80.9
Oct1
1 NNRTAATNANNN 26t o+1 79.3 77.5
Sp1
# GRGGCRGGGW 27t o+3 75.3 61.6
rs3212227 (39-UTR of IL12B):
TGTATTTGTATAGTT[A/C]GATGCTAAATGCTCA
C/EBP NNTKTGGWNANNN 213 to 21 87.7 87.7
Brn-2/Oct-3 NNCATNSRWAATNMRN 21t o+16 85.1 83.2
TATA NCTATAAAAR 211 to 22 84.7 84.7
SRY AAACWAM 210 to 24 80.9 80.9
Oct-1 TNTATGNTAATT 21t o+10 80.2 79.6
Tst-1/Oct-6 NNKGAWTWANANTKN 0 to +14 79.2 77.1
CDP CR NATYGATSSS 23t o+6 78.5 73.1
Oct-1 CWNAWTKWSATRYN 27t o+6 77.6 83.7
SRY AAACWAM 215 to 29 77.3 77.3
C/EBP NNTKTGGWNANNN 21t o+10 76.2 76.9
CDP CR NATYGATSSS 25t o+4 75.3 73.1
SRY NWWAACAAWANN 29t o+2 71.8 76.2
Binding scores differing more than 5 points between major and minor alleles are depicted in bold. Scores differing more than 10 points are depicted in bold italic.T h e
binding score threshold for each allele was set to 75.0.
{Different consensus sequences for the same transcription factor are caused by the deduction of the sequences from different matrices in the TRANSFAC database [45].
*For rs17860508, more than two alleles exist. For the major allele, the score comprises the highest score from all four non-minor alleles (-, G, GC, TTAGA). &=score for
the GC allele; #=score for the (-) allele; 1=score for the TTAGA allele.
UTR=untranslated region;
Nucleotide codes: K=G or T, M=A or C, R=A or G, S=C or G, W=A or T, N=A, G, C or T.
doi:10.1371/journal.pone.0034349.t008
IL12B in Inflammatory Bowel Disease
PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e34349rs6887695 (out of the four analyzed IL12B SNPs) the highest
likelihood of changes in transcription factor binding. This is
consistent with the results of our genotype analysis in which only
rs6887695 was associated with overall IBD susceptibility and
potential epistasis with STAT4 SNPs.
For rs6887695, the in silico analysis predicted changes in the
binding of the transcription factors HSF1, HSF2, MZF1, Oct-1
and RORa. HSF1 plays a role in protecting against DSS-
induced colitis [52]. MZF1 and Oct-1 are transcriptional
regulators of SERPINA3 [53,54] which has been implicated as
one of the epithelium-derived genes involved in the antibacterial
defense [55]. In addition, our in silico analysis predicted for the
transcription factor RORa stronger binding to the minor C
allele. Interestingly, RORa plays together with RORctak e y
role in the development of Th17 cells which are involved in the
pathogenesis of CD and UC [1] and may explain the association
of rs6887695 with increased IBD susceptibility found in our
study. Although Th17 cells are recognized as proinflammatory T
cell population, their major effector cytokines IL-17A and IL-22
may have also protective functions under certain circumstances
[19,56,57,58,59]. Similarly, studies indicated for RORa not only
proinflammatory effects but also a role as negative regulator of
inflammatory responses [60]. For example, RORa inhibits TNF-
a-induced IL-6, IL-8 and COX-2 expression in human primary
smooth-muscle cells by negatively interfering with the NF-kB
signaling pathway and reducing p65 translocation [60]. This
may correlate with our genotype-phenotype analysis which
demonstrated a less severe disease phenotype for homozygous
C/C carriers of the IL12B SNP rs6887695. CD patients, who
were homozygous C/C carriers of this SNP, had significantly
more often non-stricturing, non-penetrating disease than carriers
of the G allele (p=6.8610
25), while C/C homozygous UC
patients had less often extensive colitis than G allele carriers
(p=0.029).
IL12B is another example for a common susceptibility gene for
CD and UC which is supported by the results of our study showing
a trend for rs6887695 for association with both CD and UC. Out
of 99 currently known IBD susceptibility gene loci (71 in CD and
47 in UC), at least 28 susceptibility loci are shared between CD
and UC [9,10]. Remarkably, the strongest cluster of common CD
and UC susceptibility genes is formed by genes related to the IL-
23/Th17 pathway including IL12B [61]. Similar to IL23R, IL12B
is also a shared susceptibility gene with other IBD-associated
diseases such as psoriasis [29] and ankylosing spondylitis [28],
providing an explanation of the increased incidence of these
extraintestinal manifestations in IBD patients.
The initial GWAS focused on CD patients with ileal CD. To
exclude that the associations found in recent GWAS meta-analysis
are based only on certain IBD subphenotypes, we performed a
detailed genotype-phenotype analysis focusing also on the
anatomic disease localization. Interestingly, genotype-phenotype
analysis showed an association of IL12B rs3212227 with colonic
CD but not with ileal CD. It is likely that many of the susceptibility
loci, which are shared by CD and UC, may predispose to a
common phenotype such as colonic (and not ileal) IBD. This is
supported by the association of the IL12B SNP rs3212227 with
colonic CD and the trend for an association signal of rs6887695
with both CD and UC susceptibility found in our study. Similarly,
in another study from New Zealand, carriers of the minor C allele
of the IL12B SNP rs6887695 had a decreased risk of ileal disease
[48]. A recent study analyzing the same SNP (rs6887695)
suggested additional environmental triggers regarding the risk of
this IL12B SNP on CD susceptibility. Analyzing differences in
associated genes between smoking and non-smoking CD patients,
it implicated a complex gene-environment interaction demon-
strating an association of IL12B SNP rs6887695 in non-smoking,
but not in smoking patients [62].
In addition, our analysis of potential gene-gene interactions
revealed weak epistasis of IL12B SNP rs6887695 with 7 out of 8
analyzed STAT4 gene variants (p,0.05). This is highly interesting,
given that STAT4 is the major downstream transcription factor of
IL-12. However, considering our limited sample size and the
borderline significance of this interaction, which was lost after
Bonferroni correction, this potential gene-gene interaction needs
further analysis in very large cohorts or GWAS meta-analyses.
However, incontrastto our hypothesis-driven study,which analyzed
SNPs in the IL12B gene encoding IL-12 p40 and the gene STAT4
encoding the major IL-12 downstream transcription factor STAT4,
GWAS are limited by the problem of multiple testing to a much
greater extent than our study. Given the large number of SNPs
analyzed in GWAS, the correction factor (to correct for multiple
testing) is much higher than in our study, which may result in the
elimination of potentially true gene-gene interactions. Moreover, in
the study by Anderson et al. no formal testing for epistasis has been
performed [10]. In addition, in the manuscript by Franke et al. [9],
only epistasis between the 71 significantly associated CD loci, which
did not include STAT4,w a sa n a l y z e d .
In summary, in contrast to Th17 cell-modifying and strongly
IBD-associated IL23R gene variants, IL12B variants have a lesser
role in the susceptibility to CD and UC in the German
population, suggesting a more important role of IL-23R-
expressing Th17 cells than Th1 cells in the CD pathogenesis.
This observation is supported by similar results of large GWAS
[5,9,10], in which IL23R showed stronger associations with IBD
susceptibility than IL12B, although these GWAS clearly estab-
lished IL12B as IBD susceptibility gene. Our IL12B in silico
analysis and the results of our genotype analysis suggest
rs6887695 as likely disease-causing IL12B variant. Homozygous
C/C carriers of this SNP were protected against stricturing and
penetrating CD and showed less often extensive UC which may
be related to the alteration of the binding of certain transcription
factors such as RORa as predicted by our in silico analysis. We
demonstrated for rs688769 potential epistasis with STAT4,
encoding the major downstream transcription factor of IL-12
which would link IL-12 and STAT4 for the first time on a genetic
level. Moreover, similar to an association of the STAT4 SNP
rs7574865 with colonic CD [40], we found an association of the
IL12B SNP rs3212227 with an increased risk for colonic CD.
Based on the gene-gene interaction found for IL12B and STAT4
in this study, large meta-analyses (e.g., by the International IBD
Genetics Consortium), which may include our data should
further investigate potential epistasis between the main IBD
susceptibility genes as major pathomechanism in the disease
pathogenesis. Further fine mapping and functional studies are
required to clarify the ‘‘true’’ disease-causing IL12B variant and
its pathogenic role in IBD susceptibility.
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